Thompson David, Mackay Teresa, Matthews Maria, Edwards Judith, Peters Nicholas S, Connolly Susan B
International Centre for Circulatory Health, National Heart and Lung Institute, Imperial College London, London, United Kingdom.
Imperial College Healthcare NHS Trust, London, United Kingdom.
JMIR Mhealth Uhealth. 2017 Jun 12;5(6):e76. doi: 10.2196/mhealth.6998.
Use of appropriate cardioprotective medication is a cornerstone of cardiovascular disease prevention, but less-than-optimal patient adherence is common. Thus, strategies for improving adherence are recommended to adopt a multifaceted approach.
The objective of our study was to test a system comprising a biodegradable, ingestible sensor for direct measurement of medication ingestion in a group of patients at elevated cardiovascular risk attending a cardiac prevention and rehabilitation program.
In this prospective intervention trial in a single group of 21 patients running from April 2014 to June 2015, we measured adherence by self-report and adherence determined objectively by the system. The sensor emits a signal when it encounters the acidic environment of the stomach, detectable by an externally worn patch and linked software app. Longitudinal adherence data in the form of daily progress charts for sensed dosing events as compared with scheduled dosing are visible to patients on their tablet computer's medication dosing app, thus providing patients with continuous medication adherence feedback. We sought feedback on patient acceptability by questionnaire assessment. Participants used the system for the 12-week period of their cardiac prevention and rehabilitation program.
Only 1 patient at initial assessment and 1 patient at end-of-program assessment reported often missing medication. The remaining patients reported never missing medication or had missing data. Only 12 (57%) of patients overall achieved system-determined adherence of 80% or more, and 3 patients had scores below 40%. Participants reported high levels of acceptability.
This integrated system was well tolerated in a group of 21 patients over an appreciable time frame. Its ability to measure adherence reveals the sizeable disconnect between patient self-reported adherence and actual medication taking and has promising potential for clinical use as a tool to encourage better medication-taking behavior due to its ability to provide continuous patient-level feedback.
使用适当的心脏保护药物是预防心血管疾病的基石,但患者依从性欠佳的情况很常见。因此,建议采用多方面方法来改善依从性。
我们研究的目的是测试一种系统,该系统包含一个可生物降解的可摄入传感器,用于直接测量参加心脏预防与康复项目的心血管疾病风险升高患者群体的药物摄入情况。
在这项于2014年4月至2015年6月对21名患者组成的单组进行的前瞻性干预试验中,我们通过自我报告测量依从性,并通过该系统客观确定依从性。当传感器遇到胃的酸性环境时会发出信号,可通过外部佩戴的贴片和相关软件应用程序检测到。与预定给药相比,以每日给药事件进度图表形式呈现的纵向依从性数据在患者平板电脑的给药应用程序上可见,从而为患者提供持续的药物依从性反馈。我们通过问卷调查评估来征求患者对该系统可接受性的反馈。参与者在其心脏预防与康复项目的12周期间使用该系统。
在初始评估时只有1名患者,在项目结束评估时有1名患者报告经常漏服药物。其余患者报告从未漏服药物或数据缺失。总体而言,只有12名(57%)患者达到系统确定的80%或更高的依从性,3名患者得分低于40%。参与者报告该系统的可接受性很高。
在相当长的时间内,该集成系统在21名患者群体中耐受性良好。其测量依从性的能力揭示了患者自我报告的依从性与实际服药情况之间存在相当大的差异,并且由于其能够提供持续的患者层面反馈,作为鼓励更好服药行为的工具在临床应用中具有广阔前景。